Physician profile
Skylar Groth
NPI 1518537158
$9,561.76
in general payments reported to CMS, 2019-2025
29 companies · $5,771 in 2025
The $5,771 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $143 · 2022: $867 · 2023: $1,799 · 2024: $981 · 2025: $5,771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,943 · Consulting Fee: $2,400 · Travel and Lodging: $2,010 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,943.10 |
| Consulting Fee | $2,400.00 |
| Travel and Lodging | $2,009.63 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $3,661.70 | 2021-2025 | Jakafi, Niktimvo |
| Adaptive Biotechnologies Corporation | $2,560.21 | 2022-2025 | Clonoseq |
| Astellas Pharma US INC | $823.93 | 2022-2024 | Xospata, Cresemba |
| Astrazeneca Pharmaceuticals LP | $291.37 | 2022-2024 | Calquence |
| Celgene Corporation | $248.16 | 2022-2024 | Reblozyl, Onureg |
| Janssen Biotech, INC. | $171.75 | 2022-2023 | Imbruvica |
| Beigene USA, INC. | $153.08 | 2023-2024 | Brukinsa |
| Pharmacyclics LLC, An Abbvie Company | $148.96 | 2022-2023 | Epkinly, Imbruvica |
| Legend Biotech USA INC. | $139.31 | 2025 | Carvykti |
| E.R. Squibb & Sons, L.L.C. | $126.86 | 2023 | Reblozyl |
| Dova Pharmaceuticals | $118.70 | 2021 | |
| Sanofi-Aventis U.S. LLC | $117.73 | 2024 | |
| Gamida Cell INC. | $106.33 | 2025 | Omisirge |
| Amgen INC. | $100.37 | 2022-2023 | Blincyto, Kyprolis |
| Syndax Pharmaceuticals, INC. | $97.30 | 2025 | Revuforj |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmaessentia USA Corporation | $83.59 | 2023-2024 | Besremi |
| Cti Biopharma Corp. | $77.79 | 2023 | Vonjo |
| Pfizer INC. | $59.45 | 2022-2023 | |
| Rigel Pharmaceuticals, INC. | $57.52 | 2023-2024 | Tavalisse, Rezlidhia |
| Novartis Pharmaceuticals Corporation | $56.95 | 2023 | |
| Daiichi Sankyo INC. | $54.91 | 2023 | |
| Taiho Oncology, INC. | $52.14 | 2023 | |
| Lilly USA, LLC | $50.47 | 2023-2024 | Jaypirca |
| Sobi, INC | $45.58 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $43.92 | 2023-2025 | Keytruda Qlex, Keytruda, Welireg |
| Teleflex LLC | $37.82 | 2025 | Arrow |
| Glaxosmithkline, LLC. | $26.87 | 2023 | Ojjaara |
| Servier Pharmaceuticals LLC | $24.98 | 2023 | |
| Abbvie INC. | $24.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Skylar Groth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.